Skip to main content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Erschienen in: memo - Magazine of European Medical Oncology 2/2017

01.06.2017 | review

American Society of Hematology 2016 annual meeting

Novel strategies in the management of lymphoma

verfasst von: Daniel Heintel, MD

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 2/2017

Einloggen, um Zugang zu erhalten

Summary

At the last meeting of the American Society of Hematology (ASH), data on first-line treatment with obinutuzumab in indolent lymphoma, as well as promising data on the long-term observation of chronic lymphocytic leukemia (CLL) patients treated with ibrutinib, were presented.
In diffuse large B‑cell lymphoma (DLBCL), again, a more intensified treatment approach failed to improve patient survival. Moreover, and in contrast to indolent lymphoma, the use of obinutuzumab instead of rituximab (R) did not prove to be superior in DLBCL. However, data on lenalidomide maintenance, as well as data on novel agents in primary central nervous system lymphoma (PCNL), were presented. A survival benefit for R maintenance therapy could be shown in mantle cell lymphoma (MCL).
Literatur
1.
Zurück zum Zitat Fisher RI, et al. New treatment options have changed the survival of patients with follicular lymphoma. J Clin Oncol. 2005;23(33):8447–52. CrossRefPubMed Fisher RI, et al. New treatment options have changed the survival of patients with follicular lymphoma. J Clin Oncol. 2005;23(33):8447–52. CrossRefPubMed
2.
Zurück zum Zitat Mössner E, et al. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B‑cell cytotoxicity. Blood. 2010;115(22):4393–402. CrossRefPubMedPubMedCentral Mössner E, et al. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B‑cell cytotoxicity. Blood. 2010;115(22):4393–402. CrossRefPubMedPubMedCentral
3.
Zurück zum Zitat Marcus RE. et al. Obinutuzumab-based induction and maintenance prolongs progression-free survival (PFS) in patients with previously untreated follicular lymphoma: primary results of the randomized phase 3 GALLIUM study. 58th ASH Annual Meeting & Exposition, San Diego. 2016, p abstract 6. plenary session. Marcus RE. et al. Obinutuzumab-based induction and maintenance prolongs progression-free survival (PFS) in patients with previously untreated follicular lymphoma: primary results of the randomized phase 3 GALLIUM study. 58th ASH Annual Meeting & Exposition, San Diego. 2016, p abstract 6. plenary session.
4.
Zurück zum Zitat Cheson. et al. Obinutuzumab plus bendamustine followed by obinutuzumab maintenance prolongs overall survival compared with bendamustine alone in patients with Rituximab-refractory indolent non-Hodgkin Lymphoma: updated results of the GADOLIN study. San Diego, 58th ASH Annual Meeting & Exposition. 2016, p abstract 615. oral presentation. Cheson. et al. Obinutuzumab plus bendamustine followed by obinutuzumab maintenance prolongs overall survival compared with bendamustine alone in patients with Rituximab-refractory indolent non-Hodgkin Lymphoma: updated results of the GADOLIN study. San Diego, 58th ASH Annual Meeting & Exposition. 2016, p abstract 615. oral presentation.
5.
Zurück zum Zitat Eichhorst et al. Favorable toxicity profile and long term outcome of elderly, but physically fit CLL patients (pts) receiving first line bendamustine and rituximab (BR) frontline chemoimmunotherapy in comparison to fludarabine, cyclophosphamide, and rituximab (FCR) in advanced chronic lymphocytic leukemia (CLL): update analysis of an international, randomized study of the German CLL study group (GCLLSG) (CLL10 study). 58th ASH Annual Meeting & Exposition. 2016, p abstract 4382. poster presentation. Eichhorst et al. Favorable toxicity profile and long term outcome of elderly, but physically fit CLL patients (pts) receiving first line bendamustine and rituximab (BR) frontline chemoimmunotherapy in comparison to fludarabine, cyclophosphamide, and rituximab (FCR) in advanced chronic lymphocytic leukemia (CLL): update analysis of an international, randomized study of the German CLL study group (GCLLSG) (CLL10 study). 58th ASH Annual Meeting & Exposition. 2016, p abstract 4382. poster presentation.
6.
Zurück zum Zitat Thompson et al. Early achievement of MRD-negativity in IGHV-mutated (IGHV-M) patients portends highly favorable outcomes after first-line treatment of CLL with fludarabine, cyclophosphamide and rituximab (FCR). Serial monitoring for minimal residual disease (MRD) in blood after achieving MRD-negativity predicts subsequent clinical relapse. 58th ASH Annual Meeting & Exposition. 2016, p abstract 232. oral presentation. Thompson et al. Early achievement of MRD-negativity in IGHV-mutated (IGHV-M) patients portends highly favorable outcomes after first-line treatment of CLL with fludarabine, cyclophosphamide and rituximab (FCR). Serial monitoring for minimal residual disease (MRD) in blood after achieving MRD-negativity predicts subsequent clinical relapse. 58th ASH Annual Meeting & Exposition. 2016, p abstract 232. oral presentation.
8.
Zurück zum Zitat Barr PM. et al. Updated efficacy and safety from the phase 3 resonate-2 study: Ibrutinib as first-line treatment option in patients 65 years and older with chronic lymphocytic leukemia/small lymphocytic leukemia. 58th ASH Annual Meeting & Exposition. 2016, p abstract 234. oral presentation. Barr PM. et al. Updated efficacy and safety from the phase 3 resonate-2 study: Ibrutinib as first-line treatment option in patients 65 years and older with chronic lymphocytic leukemia/small lymphocytic leukemia. 58th ASH Annual Meeting & Exposition. 2016, p abstract 234. oral presentation.
9.
Zurück zum Zitat O’Brien SM. et al. Five-year experience with single-agent Ibrutinib in patients with previously untreated and relapsed/refractory chronic lymphocytic leukemia/small lymphocytic leukemia. 58th ASH Annual Meeting & Exposition. 2016, p abstract 233. oral presentation. O’Brien SM. et al. Five-year experience with single-agent Ibrutinib in patients with previously untreated and relapsed/refractory chronic lymphocytic leukemia/small lymphocytic leukemia. 58th ASH Annual Meeting & Exposition. 2016, p abstract 233. oral presentation.
10.
Zurück zum Zitat Jones J. et al. Venetoclax (VEN) monotherapy for patients with chronic lymphocytic leukemia (CLL) who relapsed after or were refractory to Ibrutinib or idelalisib. 58th ASH Annual Meeting & Exposition. 2016, p abstract 637. oral presentation. Jones J. et al. Venetoclax (VEN) monotherapy for patients with chronic lymphocytic leukemia (CLL) who relapsed after or were refractory to Ibrutinib or idelalisib. 58th ASH Annual Meeting & Exposition. 2016, p abstract 637. oral presentation.
11.
Zurück zum Zitat Kreuzer. et al. Outcome of patients with complex karyotype in a phase 3 randomized study of Idelalisib plus rituximab for relapsed chronic lymphocytic leukemia. 58th ASH Annual Meeting & Exposition. 2016, p abstract 192. oral presentation. Kreuzer. et al. Outcome of patients with complex karyotype in a phase 3 randomized study of Idelalisib plus rituximab for relapsed chronic lymphocytic leukemia. 58th ASH Annual Meeting & Exposition. 2016, p abstract 192. oral presentation.
12.
Zurück zum Zitat Fink. et al. Lenalidomide maintenance after front line therapy substantially prolongs progression free survival in high risk CLL: interim results of a phase 3 study (CLL M1 study of the German CLL study group). 58th ASH Annual Meeting & Exposition. 2016, p abstract 229. oral presentation. Fink. et al. Lenalidomide maintenance after front line therapy substantially prolongs progression free survival in high risk CLL: interim results of a phase 3 study (CLL M1 study of the German CLL study group). 58th ASH Annual Meeting & Exposition. 2016, p abstract 229. oral presentation.
13.
Zurück zum Zitat Foa. et al. Results of the phase 3 study of Lenalidomide versus placebo as maintenance therapy following second-line treatment for patients with chronic lymphocytic leukemia (the CONTINUUM trial). 58th ASH Annual Meeting & Exposition. 2016, p abstract 230. oral presentation. Foa. et al. Results of the phase 3 study of Lenalidomide versus placebo as maintenance therapy following second-line treatment for patients with chronic lymphocytic leukemia (the CONTINUUM trial). 58th ASH Annual Meeting & Exposition. 2016, p abstract 230. oral presentation.
14.
Zurück zum Zitat Awan. et al. Acalabrutinib monotherapy in patients with Ibrutinib intolerance: results from the phase 1/2 ACE-CL-001 clinical study. 58th ASH Annual Meeting & Exposition. 2016, p abstract 638. oral presentation. Awan. et al. Acalabrutinib monotherapy in patients with Ibrutinib intolerance: results from the phase 1/2 ACE-CL-001 clinical study. 58th ASH Annual Meeting & Exposition. 2016, p abstract 638. oral presentation.
15.
Zurück zum Zitat Wilson WH. et al. Phase III randomized study of R‑CHOP versus DA-EPOCH-R and molecular analysis of untreated diffuse large B‑cell lymphoma: CALGB/alliance 50303. 58th ASH Annual Meeting & Exposition. 2016, p abstract 469. oral presentation. Wilson WH. et al. Phase III randomized study of R‑CHOP versus DA-EPOCH-R and molecular analysis of untreated diffuse large B‑cell lymphoma: CALGB/alliance 50303. 58th ASH Annual Meeting & Exposition. 2016, p abstract 469. oral presentation.
16.
Zurück zum Zitat Vitolo U. et al. Obinutuzumab or rituximab plus CHOP in patients with previously untreated diffuse large B‑cell lymphoma: final results from an open-label, randomized phase 3 study (GOYA). 58th ASH Annual Meeting & Exposition. 2016, p abstract 470. oral presentation. Vitolo U. et al. Obinutuzumab or rituximab plus CHOP in patients with previously untreated diffuse large B‑cell lymphoma: final results from an open-label, randomized phase 3 study (GOYA). 58th ASH Annual Meeting & Exposition. 2016, p abstract 470. oral presentation.
17.
Zurück zum Zitat Thieblemont. et al. First analysis of an international double-blind randomized phase III study of lenalidomide maintenance in elderly patients with DLBCL treated with R‑CHOP in first line, the Remarc study from Lysa. 58th ASH Annual Meeting & Exposition. 2016, p abstract 471. oral presentation. Thieblemont. et al. First analysis of an international double-blind randomized phase III study of lenalidomide maintenance in elderly patients with DLBCL treated with R‑CHOP in first line, the Remarc study from Lysa. 58th ASH Annual Meeting & Exposition. 2016, p abstract 471. oral presentation.
18.
Zurück zum Zitat Neelapu SS. et al. LBA-6 Kte-C19 (anti-CD19 CAR T cells) induces complete remissions in patients with refractory diffuse large B‑cell Lymphoma (DLBCL): results from the pivotal phase 2 ZUMA-1. 58th ASH Annual Meeting & Exposition. 2016, p abstract LBA-6. oral presentation. Neelapu SS. et al. LBA-6 Kte-C19 (anti-CD19 CAR T cells) induces complete remissions in patients with refractory diffuse large B‑cell Lymphoma (DLBCL): results from the pivotal phase 2 ZUMA-1. 58th ASH Annual Meeting & Exposition. 2016, p abstract LBA-6. oral presentation.
19.
Zurück zum Zitat Choquet S. et al. Ibrutinib monotherapy in relapse or refractory primary CNS lymphoma (PCNSL) and primary vitreo-retinal lymphoma (PVRL). Result of the interim analysis of the iLOC phase II study from the Lysa and the French LOC network. 58th ASH Annual Meeting & Exposition. 2016, p abstract 784. oral presentation. Choquet S. et al. Ibrutinib monotherapy in relapse or refractory primary CNS lymphoma (PCNSL) and primary vitreo-retinal lymphoma (PVRL). Result of the interim analysis of the iLOC phase II study from the Lysa and the French LOC network. 58th ASH Annual Meeting & Exposition. 2016, p abstract 784. oral presentation.
20.
Zurück zum Zitat Grommes Ch. et al. Single-agent ibrutinib in recurrent/refractory central nervous system lymphoma. 58th ASH Annual Meeting & Exposition. 2016, p abstract 783. oral presentation. Grommes Ch. et al. Single-agent ibrutinib in recurrent/refractory central nervous system lymphoma. 58th ASH Annual Meeting & Exposition. 2016, p abstract 783. oral presentation.
21.
Zurück zum Zitat Ghesquieres H. et al. Rituximab-Lenalidomide (REVRI) in relapse or refractory primary central nervous system (PCNSL) or vitreo retinal lymphoma (PVRL): results of a “proof of concept” phase II study of the French LOC network. 58th ASH Annual Meeting & Exposition. 2016, p abstract 784. oral presentation. Ghesquieres H. et al. Rituximab-Lenalidomide (REVRI) in relapse or refractory primary central nervous system (PCNSL) or vitreo retinal lymphoma (PVRL): results of a “proof of concept” phase II study of the French LOC network. 58th ASH Annual Meeting & Exposition. 2016, p abstract 784. oral presentation.
22.
Zurück zum Zitat Le Gouill S. et al. Rituximab maintenance after autologous stem cell transplantation prolongs survival in younger patients with mantle cell lymphoma: final results of the randomized phase 3 lyma trial of the Lysa/Goelams group. 58th ASH Annual Meeting & Exposition. 2016, p abstract 145. oral presentation. Le Gouill S. et al. Rituximab maintenance after autologous stem cell transplantation prolongs survival in younger patients with mantle cell lymphoma: final results of the randomized phase 3 lyma trial of the Lysa/Goelams group. 58th ASH Annual Meeting & Exposition. 2016, p abstract 145. oral presentation.
Metadaten
Titel
American Society of Hematology 2016 annual meeting
Novel strategies in the management of lymphoma
verfasst von
Daniel Heintel, MD
Publikationsdatum
01.06.2017
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 2/2017
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-017-0340-6

Weitere Artikel der Ausgabe 2/2017

memo - Magazine of European Medical Oncology 2/2017 Zur Ausgabe